Abstract
Purpose
Polycystic ovary syndrome (PCOS) is a complex multifactorial endocrine disorder affecting approximately 5–10% of women of reproductive age. Affected women have menstrual disturbances due to anovulation, infertility, and hyperandrogenism. Ovarian androgen overproduction is the key physiopathologic feature of PCOS. A number of genes encoding major enzymes of the androgen metabolic pathways, such as HSD17B6, CYP19A1, CYP11A1, CYP17A1, and INSR, have been examined. Very few studies have been done in North India. There is an increasing prevalence of PCOS in women in Punjab and it is the leading cause of female infertility. In view of the strong evidence implicating the importance of CYP19A1 and CYP17A1 in androgen metabolic pathways, we investigated the association of rs700519, rs2414096, and rs743572 (− 34T>C) polymorphisms on susceptibility of develo** PCOS, in North India.
Methods
A total of 500 subjects (women of reproductive age) including 250 PCOS cases and 250 healthy age-matched controls were included in the present study. DNA was extracted from venous blood for all samples, and association analysis for rs2414096, rs700519, and rs743572 was done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Lipid profile was done using a biochemical analyzer and body mass index (BMI) was measured for all cases. Statistical analysis was performed.
Results
Significant association of − 34T>C polymorphism of CYP17A1 was found with PCOS (p = 0.0005). BMI was statistically different between PCOS cases and controls (p = 0.000). Triglycerides were high in PCOS women. Variations of CYP19A1 were not statistically significant with PCOS.
Conclusions
These data suggest that − 34T>C polymorphism in CYP17A1 is associated with PCOS in North India. No polymorphism of CYP19A1 was found to be associated.
Similar content being viewed by others
References
Akgul S, Derman O, Alikaşifoglu M, Aktaş D. CYP1A1 polymorphism in adolescents with polycystic ovary syndrome. Int J Gynecol Obstet. 2011;112:8–10.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome society. Fertil Steril. 2004;81:19–25.
Dumitrescu R, Mehedintu C, Briceag I, Purcarea V, Hudita D. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. J Med Life. 2015;8(2):142–5.
Nidhi R, Padmalatha V, Nagarathna R, Ram A. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol. 2011;24:223–7.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002 Jul;26(7):883–96.
Kaur A. Survey of obesity among various age group girls of Punjab. Int J Phys Educ Sports Health. 2016;3(2):296–9.
Bentley-Lewis R, Seely E, Dunaif A. Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2011;40(2):433–x.
Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1):165–9.
Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab. 1999;84(1):38–43.
Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod. 2003;18(3):598–603.
Diao FY, Xu M, Hu Y, Li J, Xu Z, Lin M, et al. The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray. J Mol Endocrinol. 2004;33:59–72.
Miller WL, Bose HS. Early steps in steroidogenesis: intracellular cholesterol trafficking: thematic review series: genetics of human lipid diseases. J Lipid Res. 2011;52(12):2111–35.
Manna PR, Stetson CL, Slominski AT, Pruitt K. Role of the steroidogenic acute regulatory protein in health and disease. Endocrine. 2016;51(1):7–21.
Harada N, Ogawa H, Shozu M, Yamada K. Genetic studies to characterize the origin of the mutation in placental aromatase deficiency. Am J Hum G E N. 1992;51:666–72.
Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci U S A. 1993;90:11673–7.
Naessen T, Kushnir MM, Chaika A, Nosenko J, Mogilevkina I, Rockwood AL, et al. Steroid profiles in ovarian follicular fluid in women with and without polycystic ovary syndrome, analyzed by liquid chromatography-tandem mass spectrometry. Fertil Steril. 2010;94(6):2228–33.
Magoffin DA. Ovarian enzyme activities in women with polycystic ovary syndrome. Fertil Steril. 2006;86:S9–S11.
Gilep AA, Sushko TA, Usanov SA. At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17. Biochim Biophys Acta. 2011;1814:200–9.
Chua AK, Azziz R, Goodarzi MO. Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage. Mol Hum Reprod. 2012;18(6):320–4.
Carey AH, Chan KL, Short F, White D, Williamson R, Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol. 1993;38(6):653–8.
Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38:209–13.
World Health Organisation (WHO). Appropriate body-mass index for Asian populations and its implications for policy and intervention for strategies. Lancet. 2004;363:157–63.
Adeli K, Ogbonna G. Rapid purification of human DNA from whole blood for potential application in clinical chemistry laboratories. Clin Chem. 1990;36(2):261–4.
Wang H, Li Q, Wang T, Yang G, Wang Y, Zhang X, et al. A common polymorphism in the human aromatase gene alters the risk for polycystic ovary syndrome and modifies aromatase activity in vitro. Mol Hum Reprod. 2011;17(6):386–91.
** JL, Sun J, Ge HJ, Cao YX, Wu XK, Liang FJ, et al. Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. BMC Med Genet. 2009;10:139.
Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG, Filandra FA, Tsianateli TC, et al. Polymorphism T→ C (− 34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril. 1999;71(3):431–5.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.
Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994;3(10):1873–6.
Kahsar-Miller M, Boots L, Bartolucci A, Azziz R. Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertil Steril. 2004;82:973–5.
Echiburú B, Pérez-Bravo F, Maliqueo M, Sánchez F, Crisosto N, Sir-Petermann T. Polymorphism T –> C (−34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study. Metabolism. 2008;57:1765–71.
Park J, Lee E, Ramakrishna S, Cha D, Baek K. Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. Int J Mol Med. 2008;22:249–54.
Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Ilke OH, et al. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet. 2009;26:205–16.
Pusalkar M, Meherji P, Gokral J, Chinnaraj S, Maitra A. CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. Fertil Steril. 2009;92:653–9.
Mohammed MB, AL-Awadi SJ, Omran MA. Association between polycystic ovary syndrome and genetic polymorphisms of CYP 17 gene in Iraqi women. Iraqi J Biotechnol. 2015;14(2):99–110.
Reddy KR, Deepika MLN, Latha KP, Sagurthi SR, Lakshmanarao SS, Rahman PF, et al. Polycystic ovary syndrome: role of aromatase gene variants in south Indian women. Int J Pharm Bio Sci. 2015;6(2):1283–96.
Mutib MT, Hamdam FB, Salihi ARA. Effect of CYP19 gene on polycystic ovary syndrome phenotype in Iraqi women. Iraqi J Med Sci. 2015;13(3):272–8.
Dou Q, Tan L, Ma LY, Sun YP. The relationship between the CYP19 alleles rs727479A/C, rs700518A/G, and rs700519C/T and pregnancy outcome after assisted reproductive technology in patients with polycystic ovary syndrome in a Chinese population: a population-based study. Kaohsiung J Med Sci. 2017;33(11):558–66.
Joshi SR. Metabolic syndrome—emerging clusters of the Indian phenotype. J Assoc Physicians India. 2003;51:445–6.
Dağ ZÖ, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16(2):111–7.
Sidhu S, Tatla HS. Prevalence of overweight and obesity among adult urban females of Punjab: a cross-sectional study. Anthropologist. 2002;4(2):101–3.
Thathapudi S, Kodati V, Erukkambattu J, Katragadda A, Addepally U, Hasan Q. Anthropometric and biochemical characteristics of polycystic ovarian syndrome in South Indian women using AES-2006 criteria. Int J Endocrinol Metab. 2014;12(1):e12470.
Deepika MLN, Ranjith K, Rani VU, Ishaq M, Jahan P. Familial background of complex diseases in PCOS probands of South Indian population. Asian J Epidemiol. 2012;5(2):50–5.
Chen J, Shen S, Tan Y, **a D, **a Y, Cao Y, et al. The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. J Ovar Res. 2015;8(11):1–6.
Alnakash Abdulrazak H, Al-Tae e NK. Polycystic ovarian syndrome: the correlation between the LH/FSH ratio and disease manifestations. Middle East Fertil Soc J. 2007;12(1):35.
Haider S, Mannan N, Khan A, Qureshi MA. Influence of anthropometric measurements on abnormal gonadotropin secretion in women with polycystic ovary syndrome. J Coll Physicians Surg Pak. 2014;24(7):463–6.
Zhang XL, Zhang CW, Xu P, Liang FJ, Che YN, **a YJ, et al. SNP rs2470152 in CYP19 is correlated to aromatase activity in Chinese polycystic ovary syndrome patients. Mol Med Rep. 2012;5:245–9.
Macut D, Panidis D, Glisić B, Spanos N, Petakov M, Bjekić J, et al. Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol. 2008;86(4):199–204.
Techatraisak K, Wongmeerit K, Dangrat C, Wongwananuruk T, Indhavivadhana S. Measures of body adiposity and visceral adiposity index as predictors of metabolic syndrome among Thai women with PCOS. Gynecol Endocrinol. 2016;32(4):276–80.
Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-γ. PPAR Res. 2007;23
Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A, et al. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens). 2006;5(1):17–34.
Gharani N, Waterworth DM, Williamson R, Franks S. 5’ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab. 1996;81(11):4174.
Guo Y, **ong DH, Yang TL, Guo YF, Recker RR, Deng HW. Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females. Hum Mol Genet. 2006;15(16):2401–8.
Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH, et al. Association of aromatase (CYP19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod. 2005;20(7):1837–43.
Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 1999;96(15):8573–8.
Söderlund D, Canto P, Carranza-Lira S, Méndez JP. No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome. Hum Reprod. 2005;20(4):965–9.
**ta N, Lazaros L, Georgiou I, Tsatsoulis A. CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. Fertil Steril. 2010;94(1):250–4.
Acknowledgements
We would like to thank patients from Hartej Hospital, Amritsar, for providing us blood samples for our study.
Funding
The study was supported by UGC-UPE (non-NET) fellowship and CPEPA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was approved by the ethics review board of Guru Nanak Dev University, consistent with provisions of the Declaration of Helsinki. Voluntary written informed consent was obtained.
Rights and permissions
About this article
Cite this article
Kaur, R., Kaur, T. & Kaur, A. Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. J Assist Reprod Genet 35, 1123–1129 (2018). https://doi.org/10.1007/s10815-018-1162-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-018-1162-0